AstraZeneca announces £16.5 million investment in Macclesfield Campus

Pharmaceuticals firm, AstraZeneca, has announced it is to invest £16.5 million into manufacturing facilities at its Macclesfield Campus.

Investment includes a £2.5 million capital grant from the Government’s Medicines and Diagnostics Manufacturing Transformation Fund that was confirmed by Science Minister George Freeman at the Medicines Manufacturing Industry Partnership conference on 21st June.

The investment will fund a small scale continuous Active Pharmaceutical Ingredient manufacturing facility to deliver clinical trial scale volumes of potential new medicines. The move will enable AstraZeneca to continue to build upon the flexible and sustainable manufacturing capabilities already at the Macclesfield Campus that will continue to develop and supply life-changing medicines to patients.

Andy Evans, VP Clinical Manufacturing & Supply at AZ Macclesfield, said:

“This investment means we will be using the latest innovative technology on campus to help develop medicines faster as well as helping to reduce our carbon footprint  – one of our top priorities for the site.”

David Rutley, Work and Pensions Minister and MP for Macclesfield, said:

“It’s great to see further investment being made at AstraZeneca’s Macclesfield Campus which plays such a key role in the local and national economy. I’m delighted that the Government has been able to support the use of cutting edge technologies that will be so important in the future of sustainable manufacturing.”